Develops and markets over-the-counter medications for pain relief, cold and allergy, and digestive health. Now — the numbers.
Revenue is spread across several lines; no single product carries the company.
This is an established company with proven profits.
The gap is $7.5B. In times of high interest rates, a gap like that can squeeze a company.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly above the class average — a step short of the very top.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades 35% below its peak. The market has trimmed its expectations for the company.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 88 buys and 72 sells. Management buying with its own money is usually read as a good sign.
It pays out $0.83 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales grew only 0% a year on average — the report card’s higher growth grade leans on profit power instead.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 43/100.
On our five-subject report card, KVUE sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: KVUE is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.